Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study

References

• American Diabetes Association. Standards of medical care Diabetes–2017: summary of revisions. Diabetes Care. 2017;40(Suppl. 1): S4–S5.
   PubMed Web of Science ®Google Scholar
• Montvida O, Shaw J, Atherton JJ, et al. Long-term trends in anti-diabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78.
   PubMed Web of Science ®Google Scholar
• Paul SK, Maggs D, Klein K, et al. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. J Diabetes. 2015;7(1):60–67.
   PubMed Web of Science ®Google Scholar
• Waldrop G, Zhong J, Peters M, et al. Incretin-based therapy in type 2 diabetes: an evidence-based systematic review and meta-analysis. J Diabetes Complications. 2018;32(1):113–122.
   PubMed Web of Science ®Google Scholar
• Mamza J, Mehta R, Donnelly R, et al. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med. 2016;48(4):224–234.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Tunceli K, Qiu Y, et al. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Diabetes Obes Metab. 2015;17(10):956–964.
   PubMed Web of Science ®Google Scholar
• Chiang CW, Chiu HF, Chen CY, et al. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997–2003. J Clin Pharm Ther. 2006;31(1):73–82.
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380.
   PubMed Web of Science ®Google Scholar
• Timar R, Velea I, Timar B, et al. Factors influencing the quality of life perception in patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10:2471–2477.
   PubMed Web of Science ®Google Scholar
• Ji L, Bonnet F, Charbonnel B, et al. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: rationale and methods of the DISCOVER observational study program. J Diabetes Complications. 2017;31(7):1188–1196.
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Takahara M, et al. Rationale and design for the J-DISCOVER study: DISCOVERing the treatment reality of type 2 diabetes in a real-world setting in Japan – a protocol. Diabetes Ther. 2018;9(1):165–175.
   PubMed Web of Science ®Google Scholar
• Ware J, Snow K, Kosinski M, et al. SF-36 health survey: manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center; 1993.
   Google Scholar
• Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user’s manual. Boston (MA): The Health Institute, New England Medical Center; 1994.
   Google Scholar
• Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab. 2019;21(11):2474–2485.
   PubMed Web of Science ®Google Scholar
• Feldman BS, Cohen-Stavi CJ, Leibowitz M, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLOS One. 2014;9(9):e108145.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2009;32(1):193–203.
   PubMed Web of Science ®Google Scholar
• Bazargani YT, de Boer A, Leufkens HG, et al. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. PLOS One. 2014;9(9):e106072.
   PubMed Web of Science ®Google Scholar
• Reach G, Pechtner V, Gentilella R, et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–511.
   PubMed Web of Science ®Google Scholar
• Al-Rubeaan K, Bana FA, Alruwaily FG, et al. Physicians’ choices in the first-and second-line management of type 2 diabetes in the kingdom of Saudi Arabia. Saudi Pharm J. 2020;28(3):329–337.
   PubMed Web of Science ®Google Scholar
• Chu WM, Ho HE, Huang KH, et al. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study. Medicine. 2017;96(43):e8257.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–2135.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang X, Korantzopoulos P, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord. 2017;17(1):9.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–S80.
   PubMed Web of Science ®Google Scholar
• Health G. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 2021;9:825–836.
   PubMed Web of Science ®Google Scholar
• Tummalapalli SL, Montealegre JL, Warnock N, et al. Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum. 2021;2(12):e214205.
   PubMedGoogle Scholar
• Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care. 2007;30(6):1448–1453.
   PubMed Web of Science ®Google Scholar
• Toroski M, Kebriaeezadeh A, Esteghamati A, et al. Patient and physician preferences for type 2 diabetes medications: a systematic review. J Diabetes Metab Disord. 2019;18(2):643–656.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9: Cardiovascular disease and risk management. Diabetes Care. 2017;40(Suppl 1):S75–S87.
   PubMedGoogle Scholar
• Fung CSC, Wan EYF, Chan AKC, et al. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord. 2017;17(1):166.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhuang X, Chen X, et al. Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a perspective from the guideline appraisal. J Diabetes Investig. 2021;12(1):99–108.
   PubMed Web of Science ®Google Scholar
• Schunk M, Reitmeir P, Rückert-Eheberg IM, et al. Longitudinal change in health-related quality of life in people with prevalent and incident type 2 diabetes compared to diabetes-free controls. PLOS One. 2017;12(5):e0176895.
   PubMed Web of Science ®Google Scholar
• Frendl DM, Ware JE Jr. Patient-reported functional health and well-being outcomes with drug therapy: a systematic review of randomized trials using the SF-36 health survey. Med Care. 2014;52(5):439–445.
   PubMed Web of Science ®Google Scholar
• Maruish ME. User’s manual for the SF-36v2 health survey. 3rd ed. Lincoln (RI): Quality Metric Incorporated; 2011.
   Google Scholar
• Nomura M, Fujimoto K, Higashino A, et al. Stress and coping behavior in patients with diabetes mellitus. Acta Diabetol. 2000;37(2):61–64.
   PubMed Web of Science ®Google Scholar
• Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. J Postgrad Med. 2004;50(3):189–193; discussion 194.
   PubMedGoogle Scholar